: Clinical studies show that roughly 67.2% of patients remain recurrence-free for at least six months after treatment.
The availability of Uro-Vaxom varies significantly by region:
: It is not widely available; other alternatives like Uromune have previously had special ordering mechanisms, but these are often paused.